STOCK TITAN

[DEFA14A] Immunovant, Inc. Additional Proxy Soliciting Materials

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
DEFA14A
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934
(Amendment No.    )

Filed by the Registrant ☒    
Filed by a Party other than the Registrant ☐


Check the appropriate box:

☐    Preliminary Proxy Statement

☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐     Definitive Proxy Statement

☒     Definitive Additional Materials

☐    Soliciting Material Pursuant to § 240.14a-12

IMMUNOVANT, INC.

(Name of Registrant as Specified In Its Charter)


Payment of Filing Fee (Check all boxes that apply):
☒     No fee required.

☐     Fee paid previously with preliminary materials.

☐     Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11























immunovantinc_vxnaxp35765x.jpg

























immunovantinc_vxnaxp35765xa.jpg





















Immunovant Inc

NASDAQ:IMVT

IMVT Rankings

IMVT Latest News

IMVT Latest SEC Filings

IMVT Stock Data

2.90B
68.00M
58.08%
47.58%
9.06%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK